Senators Press HHS on Prediction Markets That Bet on Drug Approvals

Two senators want to know what the federal health department is doing about online prediction markets that let people trade on the outcomes of clinical trials and drug approvals. Sens. Angela Alsobrooks and Ron Wyden have asked the Department of Health and Human Services to explain what steps it has taken to reduce the risks these markets create.

The concern is easy to follow. A prediction market pays out depending on whether an event happens, so a trader who knows how a trial is going, or when a regulator is likely to act, can profit from that knowledge before the public has it. Many of the people closest to such information work inside drug companies, research sites, or government agencies, which raises the prospect of insiders betting on results they are not supposed to share.

The letter also reflects a wider debate about whether markets built around health outcomes should exist at all, and who should oversee them. Trial results and approval decisions do more than move money. They shape patient care, investor expectations, and public trust in the agencies that review drugs. Lawmakers are signaling that they want to know whether the executive branch has a plan for those effects, not only whether a rule happens to apply.

The available reporting does not say how HHS has responded, or whether the senators have set a deadline for an answer. Those details will show how seriously the department is treating the issue. Readers should also watch whether other regulators with authority over event contracts take up the same questions, since oversight of these markets is split across more than one agency.